1. Clinical experience of CT-P6 for HER2 positive breast cancer: a case series. (March 2019) Authors: Jeon, C.W.; Choi, J.H.; Jung, S.U.; Kim, A.L.; Lee, S.A.; Woo, S.U.; Suh, Y.J. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical pathological association with breast cancer gene analysis through next generation sequencing. (October 2020) Authors: Jung, S.; Jeon, C.W.; Choi, J.; Hyun, D.; Lee, H.; Kwon, K.; Yoon, H. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Correlation between HER2/CEP17 ratio and neoadjuvant trastuzumab and pertuzumab pathologic complete response. (March 2019) Authors: Choi, J.; Jeon, C.W.; Jung, S.U.; Kim, A.L.; Lee, S.A.; Woo, S.U.; Suh, Y.J. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Density of resected breast tissue in skin sparing total mastectomy. (March 2019) Authors: Jeon, C.W.; Choi, J.H.; Jung, S.U.; Kim, A.L.; Lee, S.A.; Woo, S.U.; Suh, Y.J. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Detection of heterozygous mutations in circulating tumor cells separated by lateral magnetophoretic microseparator. (March 2019) Authors: Jeon, C.W.; Choi, J.H.; Jung, S.U.; Kim, A.L.; Lee, S.A.; Woo, S.U.; Suh, Y.J. Journal: Breast Issue: Volume 44(2019)Supplement 1 Page Start: S36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Detection of heterozygous mutations in circulating tumor cells separated by lateral magnetophoretic microseparator. Issue 2 (February 2019) Authors: Choi, J.; Jeon, C.W.; Cho, H.; Kim, J.; Han, K.H.; Kim, A.L.; Jung, S.U. Journal: European journal of surgical oncology Issue: Volume 45:Issue 2(2019) Page Start: e91 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer. (October 2020) Authors: Jung, S.; Jeon, C.W.; Choi, J.; Hyun, D.; Lee, H.; Kwon, K.; Yoon, H. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 1 Page Start: S59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Pathological Complete response to neoadjuvant trastuzumab and pertuzumab therapy is dependent on HER2/CEP17 ratio in HER2-positive breast cancer. Issue 2 (February 2019) Authors: Choi, J.; Jeon, C.W.; Kim, A.L.; Jung, S.U. Journal: European journal of surgical oncology Issue: Volume 45:Issue 2(2019) Page Start: e101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗